UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 71

Sortiert nach

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study

Journal of clinical oncology, 2017-04, Vol.35 (10), p.1112-1118

2017

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine

Clinical cancer research, 2019-03, Vol.25 (6), p.1727-1736

2019

Link zum Volltext

Verfügbarkeit prüfen

A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer

Future oncology (London, England), 2018-01, Vol.14 (2), p.123-136

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study

Gynecologic oncology, 2018-09, Vol.150 (3), p.466-470

2018

Link zum Volltext

Verfügbarkeit prüfen

First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors

Clinical cancer research, 2017-10, Vol.23 (19), p.5703-5710

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

Gynecologic oncology, 2020-05, Vol.157 (2), p.379-385

2020

Link zum Volltext

Verfügbarkeit prüfen

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

The New England journal of medicine, 2016-02, Vol.374 (8), p.738-748

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma

Gynecologic oncology, 2015-02, Vol.136 (2), p.246-253

2015

Link zum Volltext

Verfügbarkeit prüfen

Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age?

The oncologist (Dayton, Ohio), 2019-04, Vol.24 (4), p.425-429

2019

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma

Molecular cancer therapeutics, 2015-11, Vol.14 (11), p.2569-2575

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies

Gynecologic oncology, 2018-03, Vol.148 (3), p.507-514

2018

Link zum Volltext

Verfügbarkeit prüfen

Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer

Gynecologic oncology, 2018-10, Vol.151 (1), p.46-52

2018

Link zum Volltext

Verfügbarkeit prüfen

Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine

Gynecologic oncology, 2017-11, Vol.147 (2), p.402-407

2017

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

Journal of clinical oncology, 2016-07, Vol.34 (19), p.2279-2286

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer

Gynecologic oncology, 2024-06, Vol.185, p.186-193

2024

Link zum Volltext

Verfügbarkeit prüfen

[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study

Clinical cancer research, 2023-04, Vol.29 (8), p.1515-1527

2023

Link zum Volltext

Verfügbarkeit prüfen

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

The New England journal of medicine, 2023-12, Vol.389 (23), p.2162-2174

2023

Link zum Volltext

Verfügbarkeit prüfen

Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study

Gynecologic oncology, 2019-12, Vol.155 (3), p.420-428

2019

Link zum Volltext

Verfügbarkeit prüfen

Management of Recurrent Ovarian Carcinoma: Current Status and Future Directions

Seminars in oncology, 2009-04, Vol.36 (2), p.112-125

2009

Link zum Volltext

Verfügbarkeit prüfen

Distress and Financial Distress in Adults With Cancer: An Age-Based Analysis

Journal of the National Comprehensive Cancer Network, 2017-10, Vol.15 (10), p.1224

2017

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the management of PARP inhibitor toxicities in ovarian and endometrial cancer within a multi-institution health-system

Journal of oncology pharmacy practice, 2022-07, Vol.28 (5), p.1102-1110

2022

Link zum Volltext

Verfügbarkeit prüfen

Network Analysis Identifies an HSP90-Central Hub Susceptible in Ovarian Cancer

Clinical cancer research, 2013-09, Vol.19 (18), p.5053-5067

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study

Gynecologic oncology, 2012-12, Vol.127 (3), p.451-455

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 71

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(65)

Publikationsform

Sprache

Englisch
(71)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(30)
Science & Technology
(30)
Oncology
(28)
Female
(24)
Humans
(24)
Middle Aged
(18)
Aged
(17)
Adult
(15)
Ovarian Neoplasms - Drug Therapy
(15)
Ovarian Cancer
(13)
Obstetrics & Gynecology
(11)
Aged, 80 And Over
(9)
Neoplasm Recurrence, Local - Drug Therapy
(7)
Chemotherapy
(6)
Disease-Free Survival
(6)
Antineoplastic Agents - Adverse Effects
(5)
Antineoplastic Agents - Therapeutic Use
(5)
Clinical Trial
(5)
Drug Resistance, Neoplasm
(5)
Male
(5)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

11 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine

A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer

Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study

First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors

Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma

Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age?

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer

A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma

Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies

Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer

Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine

Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer

[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study

Management of Recurrent Ovarian Carcinoma: Current Status and Future Directions

Distress and Financial Distress in Adults With Cancer: An Age-Based Analysis

Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial

Evaluation of the management of PARP inhibitor toxicities in ovarian and endometrial cancer within a multi-institution health-system

Network Analysis Identifies an HSP90-Central Hub Susceptible in Ovarian Cancer

Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study

Suchergebnisse filtern